GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSXpA.PFD) » Definitions » Debt-to-Asset
中文

Boston Scientific (Boston Scientific) Debt-to-Asset : 0.27 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Boston Scientific Debt-to-Asset?

Boston Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $531.00 Mil. Boston Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8,961.00 Mil. Boston Scientific's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $35,136.00 Mil. Boston Scientific's debt to asset for the quarter that ended in Dec. 2023 was 0.27.


Boston Scientific Debt-to-Asset Historical Data

The historical data trend for Boston Scientific's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Debt-to-Asset Chart

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.31 0.29 0.29 0.27

Boston Scientific Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.29 0.28 0.27 0.27

Competitive Comparison of Boston Scientific's Debt-to-Asset

For the Medical Devices subindustry, Boston Scientific's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Debt-to-Asset falls into.



Boston Scientific Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Boston Scientific's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Boston Scientific's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boston Scientific  (NYSE:BSXpA.PFD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Boston Scientific Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific (Boston Scientific) Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.